Pancreatic Ductal Adenocarcinoma Clinical Trials

369 clinical trials for Pancreatic Ductal Adenocarcinoma across international registries, including 127 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma — RECRUITING · PHASE3
• A Study of Nuzefatide Pevedotin (BT5528) in Patients With Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) — RECRUITING · PHASE2
• A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer — RECRUITING · PHASE2
• A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors — RECRUITING · PHASE1
• A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations — RECRUITING · PHASE1
• Study of 203Pb-RMX-VH-PIB Dosimetry and Biodistribution in Patients With Glioblastoma Multiform (GBM) and Pancreatic Ductal Adenocarcinoma (PDAC) — RECRUITING · PHASE1
• A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer — RECRUITING · PHASE1
• AB122 Platform Study — RECRUITING · PHASE1
• Neoadjuvant Folfirinox Combined With Pembrolizumab Followed by Surgery for Patients With Resectable Pancreatic Cancer — RECRUITING · PHASE2
• Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors — RECRUITING · PHASE1
• Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 ) — RECRUITING · PHASE3
• A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors — RECRUITING · PHASE1
• Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors — RECRUITING · PHASE1
• Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers — RECRUITING · PHASE1
• AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2 — RECRUITING · PHASE2
• EUS-RFA PANCARDINAL-1 Trial — RECRUITING · PHASE2
• A Clinical Trial Testing the Safety of Pumitamig (an Investigational Drug) and How Well it Works When Combined With Chemotherapy for People Who Have Not Been Treated Yet for Pancreatic Cancer — RECRUITING · PHASE2
• Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors — RECRUITING · PHASE1
• AI Derived Biomarker to Select Neoadjuvant Treatment for Borderline Resectable Pancreatic Ductal Adenocarcinoma — RECRUITING
• Panuri Performance Study — RECRUITING
• Study of IBI3028 in Participants With Locally Advanced, Unresectable, or Metastatic Solid Tumors — RECRUITING · PHASE1
• A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors — RECRUITING · PHASE1
• Pancreatic Cancer Early Detection Consortium — RECRUITING
• Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma — RECRUITING · PHASE3
• Safety of RAD301 in Healthy Human Volunteers and Patients With Pancreatic Cancer or Other Solid Tumors — RECRUITING · PHASE1
• Pancreatic Cancer Detection Consortium — RECRUITING
• [68Ga]BED003 PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications — RECRUITING · PHASE2
• A Study of ASP2138 Given Before Surgery, Then Chemotherapy After Surgery, in People With Pancreatic Ductal Cancer — RECRUITING · PHASE1
• Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors — RECRUITING · PHASE1
• Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or ICI, for the Treatment of Patients With Advanced Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study) — RECRUITING · PHASE1
• A Noninvasive and Screening miRNA Signature for Gastrointestinal Cancer — RECRUITING
• Lead-212 PSV359 Therapy for Patients With Solid Tumors — RECRUITING · PHASE1
• Patient-Derived Organoid-on-a-Chip Model for Personalized Prediction of Chemotherapy Efficacy in Pancreatic Cancer — RECRUITING
• A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A) — RECRUITING · PHASE1
• Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Pancreatic Ductal Adenocarcinoma (PDAC) — RECRUITING · PHASE3
• [18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications — RECRUITING · PHASE1
• Durvalumab and Oleclumab in Resectable PDAC — RECRUITING · PHASE2
• Liquid Biopsy and Pancreas Cancer: Detection of AXL(+) CTCs (CTC-AXL-PANC) — RECRUITING · NA
• MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors — RECRUITING · PHASE1
• Study to Evaluate the Diagnostic Performance of GEH300079 (68Ga) Injection PET/CT for Detection of PC in Patients With Colorectal, Gastric, Ovarian, or Pancreatic Cancers (PERISCOPE) — RECRUITING · PHASE2
• Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors — RECRUITING · PHASE1
• Maintenance Combinatorial Myeloid Immunotherapy for Unresectable Pancreatic Cancer — RECRUITING · PHASE2
• Cemiplimab Plus Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma — RECRUITING · PHASE2
• KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors — RECRUITING · PHASE1
• A Study of NALIRIFOX in Combination With Radiation Therapy in People With Pancreatic Ductal Adenocarcinoma (PDAC) — RECRUITING · PHASE2
• Dual-Target CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma — RECRUITING · PHASE1
• Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors — RECRUITING · PHASE1
• IBI343 in Combination Therapy for Advanced Malignant Solid Tumors — RECRUITING · PHASE2
• A Study to Determine the Effect of CT3001 in Patients With Advanced Solid Tumors — RECRUITING · PHASE1
• Prospective Screening for Pancreatic Ductal Adenocarcinoma in High-Risk Individuals — RECRUITING · PHASE1

Refine this search